Literature DB >> 26943719

Management of Hypoparathyroidism: Summary Statement and Guidelines.

Maria Luisa Brandi1, John P Bilezikian1, Dolores Shoback1, Roger Bouillon1, Bart L Clarke1, Rajesh V Thakker1, Aliya A Khan1, John T Potts1.   

Abstract

OBJECTIVE: Hypoparathyroidism is a rare disorder characterized by hypocalcemia and absent or deficient PTH. This report presents a summary of current information about epidemiology, presentation, diagnosis, clinical features, and management and proposes guidelines to help clinicians diagnose, evaluate, and manage this disorder. PARTICIPANTS: Participants in the First International Conference on the Management of Hypoparathyroidism represented a worldwide constituency with acknowledged interest and expertise in key basic, translational, and clinical aspects of hypoparathyroidism. Three Workshop Panels were constituted to address questions for presentation and discussion at the Conference held in Florence, Italy, May 7-9, 2015. At that time, a series of presentations were made, followed by in-depth discussions in an open forum. Each Workshop Panel also met in closed sessions to formulate the three evidence-based reports that accompany this summary statement. An Expert Panel then considered this information, developed summaries, guidelines, and a research agenda that constitutes this summary statement. EVIDENCE: Preceding the conference, each Workshop Panel conducted an extensive literature search as noted in the individual manuscripts accompanying this report. All presentations were based upon the best peer-reviewed information taking into account the historical and current literature. CONSENSUS PROCESS: This report represents the Expert Panel's synthesis of the conference material placed in a context designed to be relevant to clinicians and those engaged in cutting-edge studies of hypoparathyroidism.
CONCLUSIONS: This document not only provides a summary of our current knowledge but also places recent advances in its management into a context that should enhance future advances in our understanding of hypoparathyroidism.

Entities:  

Mesh:

Year:  2016        PMID: 26943719     DOI: 10.1210/jc.2015-3907

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  74 in total

Review 1.  Hypoparathyroidism.

Authors:  John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2020-06-01       Impact factor: 5.958

Review 2.  Diagnosis and management of hypocalcemia.

Authors:  Jessica Pepe; Luciano Colangelo; Federica Biamonte; Chiara Sonato; Vittoria Carmela Danese; Veronica Cecchetti; Marco Occhiuto; Valentina Piazzolla; Viviana De Martino; Federica Ferrone; Salvatore Minisola; Cristiana Cipriani
Journal:  Endocrine       Date:  2020-05-04       Impact factor: 3.633

3.  Teriparatide (rhPTH 1-34) treatment in the pediatric age: long-term efficacy and safety data in a cohort with genetic hypoparathyroidism.

Authors:  Gerdi Tuli; Raffaele Buganza; Daniele Tessaris; Silvia Einaudi; Patrizia Matarazzo; Luisa de Sanctis
Journal:  Endocrine       Date:  2019-11-08       Impact factor: 3.633

Review 4.  Primary Hyperparathyroidism.

Authors:  John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2018-11-01       Impact factor: 5.958

5.  Efficacy and safety of long-term management of patients with chronic post-surgical hypoparathyroidism.

Authors:  A Meola; E Vignali; A Matrone; F Cetani; C Marcocci
Journal:  J Endocrinol Invest       Date:  2018-03-07       Impact factor: 4.256

6.  Quality of Life in Hypoparathyroidism Improves With rhPTH(1-84) Throughout 8 Years of Therapy.

Authors:  Gaia Tabacco; Yu-Kwang Donovan Tay; Natalie E Cusano; John Williams; Beatriz Omeragic; Rukhana Majeed; Maximo Gomez Almonte; Mishaela R Rubin; John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2019-07-01       Impact factor: 5.958

7.  Recombinant Parathyroid Hormone Versus Usual Care: Do the Outcomes Justify the Cost?

Authors:  Kathryn H Chomsky-Higgins; Holly M Rochefort; Carolyn D Seib; Jessica E Gosnell; Wen T Shen; Quan-Yang Duh; Insoo Suh
Journal:  World J Surg       Date:  2018-02       Impact factor: 3.352

8.  Prevalence and risk factors for hypoparathyroidism following total thyroidectomy in Spain: a multicentric and nation-wide retrospective analysis.

Authors:  Juan J Díez; Emma Anda; Julia Sastre; Begoña Pérez Corral; Cristina Álvarez-Escolá; Laura Manjón; Miguel Paja; Marcel Sambo; Piedad Santiago Fernández; Concepción Blanco Carrera; Juan C Galofré; Elena Navarro; Carles Zafón; Eva Sanz; Amelia Oleaga; Orosia Bandrés; Sergio Donnay; Ana Megía; María Picallo; Cecilia Sánchez Ragnarsson; Gloria Baena-Nieto; José Carlos Fernández García; Beatriz Lecumberri; Manel Sahún de la Vega; Ana R Romero-Lluch; Pedro Iglesias
Journal:  Endocrine       Date:  2019-07-17       Impact factor: 3.633

Review 9.  Management of Hypoparathyroidism: Present and Future.

Authors:  John P Bilezikian; Maria Luisa Brandi; Natalie E Cusano; Michael Mannstadt; Lars Rejnmark; René Rizzoli; Mishaela R Rubin; Karen K Winer; Uri A Liberman; John T Potts
Journal:  J Clin Endocrinol Metab       Date:  2016-03-03       Impact factor: 5.958

10.  Prevalence of Nephrocalcinosis in Pseudohypoparathyroidism: Is Screening Necessary?

Authors:  David W Hansen; Todd D Nebesio; Linda A DiMeglio; Erica A Eugster; Erik A Imel
Journal:  J Pediatr       Date:  2018-04-23       Impact factor: 4.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.